title: Halozyme
id: 53139280
Halozyme Therapeutics Inc is an American biotechnology company It develops oncology therapies designed to target the tumor microenvironment br The company was founded in and went public in Halozyme is headquartered in San Diego California br br br Company history br Halozyme s business is primarily focused on its proprietary and patented recombinant human hyaluronidase enzyme rHuPH The company s development pipeline is concentrated in clinical stage and pre clinical stage oncology products including its proprietary investigational drug PEGPH a pegylated version of rHuPH which targets hyaluronan HA high tumors The company is in various phases of clinical trials with PEGPH across multiple solid tumor types including pancreatic cancer non small cell lung cancer NSCLC and gastric cancer to test the drug s safety and efficacy Halozyme has one FDA approved product Hylenex recombinant hyaluronidase human injection The company also licenses its drug delivery technology Enhanze to other biopharmaceutical companies including Roche Baxalta Pfizer Janssen AbbVie br Bristol Myers Squibb and Lilly br br br Company leadership br Since January Helen Torley has been Chief Executive Officer and President of Halozyme br br br Approved products br Hylenex Approved by the U S Food and Drug Administration FDA on Hylenex is a hyaluronidase human recombinant injection indicated for use in subcutaneous fluid administration dispersion and absorption of injected drugs and subcutaneous urography br br br Technology br Enhanze Uses recombinant human hyaluronidase to degrade HA and aids in the absorption and dispersion of co administered injected drugs Halozyme licenses its Enhanze drug delivery platform technology to other biopharmaceutical companies to enable intravenous to subcutaneous administration conversion and dose optimization br br br Product candidates br PEGPH A PEGylated drug candidate based on Halozyme s proprietary rHuPH enzyme a recombinant human hyaluronidase enzyme It breaks down or depletes hyaluronan HA which can build up in certain tumors The goal of PEGPH is to break down HA so that some anti cancer therapies and activated immune cells can better reach the cancer cells of HA high tumors On November Halozyme announced it has halted development of PEGPH br br br Pipeline candidates br PEG ADA An engineered human recombinant enzyme adenosine deaminase for decreasing the concentration of immune suppressive adenosine in the tumor microenvironment and PEGylated to prolong its circulation in the body It has been tested in colon lung and pancreatic cancer models in preclinical studies br HTI Anti EGFR ADC An antibody drug conjugate ADC with a strong cytotoxin monomethyl auristatin E designed to treat EGFR positive tumors including those with KRAS and BRAF mutations It has been tested in colon lung and cholangiocarcinoma models in preclinical studies br br br Clinical trial pipeline br Halozyme has many ongoing and completed clinical trials testing the safety and efficacy of its primary investigational drug PEGPH in combination with other therapies with the goal of finding new treatments for pancreatic cancer NSCLC gastric cancer breast cancer and others As of October the company was sponsoring or collaborating on several clinical trials that were recruiting patients including br br HALO Pancreatic A Phase study to test the efficacy and safety of a combination of PEGPH with Abraxane nab paclitaxel and gemcitabine in participants with previously untreated HA high stage IV pancreatic cancer On November Halozyme announced it has halted development of PEGPH br HALO Lung Gastric A Phase b study to test the efficacy and safety of a combination of PEGPH and Keytruda pembrolizumab in participants with relapsed refractory advanced or metastatic NSCLC and relapsed refractory locally advanced or metastatic gastric adenocarcinoma br A Phase b study to test the efficacy and safety of a combination of PEGPH with Halaven eribulin in participants with human epidermal growth factor receptor HER negative HA high metastatic breast cancer MBC br br br br br br External links br Official website br Business data for Halozyme Therapeutics Inc 